AIM
ACRS icon

Alambic Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

Alambic Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-59,766
Closed -$154K – 2
2020
Q3 		$154K Sell
59,766
-30,920
-34% -$69.2K 1.69% 21
2020
Q2 		$147K Sell
90,686
-7,600
-8% -$10.2K 0.37% 112
2020
Q1 		$102K Sell
98,286
-16,750
-15% -$22.8K 0.25% 130
2019
Q4 		$217K Sell
115,036
-35,600
-24% -$59K 0.18% 202
2019
Q3 		$163K Buy
150,636
+97,936
+186% +$139K 0.12% 230
2019
Q2 		$115K Buy
+52,700
New +$287K 0.07% 264

Other funds holding ACRS

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $965M AUM 79.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return